Araclon Biotech

Araclon Biotech, founded in 2004 and based in Zaragoza, Spain, is a Grifols subsidiary dedicated to tackling Alzheimer's Disease through early diagnostics and active immunotherapy. Its core technology platform centers on measuring amyloid-beta peptides (Aβ40 and Aβ42) in blood plasma, providing a less invasive alternative to cerebrospinal fluid or PET imaging for early detection. The company's lead therapeutic candidate, ABvac40, is an active vaccine targeting the Aβ40 peptide, and it has begun preclinical research into Parkinson's disease through a collaboration with the Spanish National Research Council (CSIC). As a fully integrated R&D unit within Grifols, Araclon leverages its parent company's resources while pursuing a high-risk, high-reward strategy in the neurodegenerative disease space.

Proprietary immunoassays for the detection and quantification of amyloid-beta peptides (Aβ40 and Aβ42) in blood plasma, and an active immunotherapy (vaccine) platform targeting specific amyloid peptides.

In diagnostics, Araclon competes with other blood-based biomarker developers (e.g., for p-tau) and established CSF/PET methods. Therapeutically, ABvac40 competes in the anti-amyloid space against approved monoclonal antibodies (lecanemab, aducanumab) and other vaccines in development. Its differentiation lies in targeting Aβ40 and its active immunization approach.